WEN Hai-tao, LIU Can-jun. Influence of Kangdu Huazhuo Decoction on Capsid Antigen IgA and Early Antigen-IgA Antibodies Infected by EB Virus[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(11): 190-193.
WEN Hai-tao, LIU Can-jun. Influence of Kangdu Huazhuo Decoction on Capsid Antigen IgA and Early Antigen-IgA Antibodies Infected by EB Virus[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(11): 190-193. DOI: 10.13422/j.cnki.syfjx.2015110190.
Objective: To observe the effect of Kangdu Huazhuo decoction on capsid antigen IgA (VCA-IgA) and early antigen-IgA (EA-IgA) antibodies of patients infected by the EB virus (EBV)
and to investigate its influence on inflammatory factor of body immunity. Method: One hundred and eighteen patients with positive EB virus (EBV) antibodies were randomly divided into the control group (37 cases) and the experimental group (81 cases) by a random number table. Patients in the control group received placebo of Kangdu Huazhuo decoction
and patients in the experimental group took Kangdu Huazhuo decoction orally. All patients in both two groups received 12 weeks of treatment. Before and after treatment
levels of VCA-IgA
EA-IgA
T lymphocyte subsets
natural killer cell(NK)
tumor necrosis factor-α(TNF-α)
interleukin-2 (IL-2) and interleukin-6 (IL-6) were detected. Result: After treatment
levels of VCA-IgA and EA-IgA in the experimental group were lower than those in the control group (P <0.01). Negative rates of VCA-IgA and EA-IgA in the experimental group were 44.15% and 41.33%
respectively
which were higher than those of 19.35% and 16.66% in the control group (P <0.05). Compared with before
levels of CD3+
CD4+
CD4+/CD8+and NK increased after treatment
and the results were higher in the experimental group (P <0.01). Levels of TNF-α and IL-6 were lower
level of IL-2 was higher in the experimental group than those in the control group after treatment (P <0.01). Conclusion: Kangdu Huazhuo decoction could reduce the levels of VCA-IgA and EA-IgA of patients with positive EBV antibodies
and promote the negative rate of VCA-IgA and EA-IgA. Its mechanism of action may be related to ameliorating cytokines and improving levels of immune function.